(CercleFinance.com) – The Theradiag share rose slightly by 0.7% on the Paris Stock Exchange on Monday, investors being reassured by the unsurprising activity figures published in the morning by the diagnostics specialist .
The group reported annual revenue of 12.2 million euros for the 2022 financial year, up 9.7%, notably under the effect of solid export performance ( excluding the United States) materialized by an increase of +23.3%.
In ‘theranostics’ (combination of treatment and diagnosis that measures the effectiveness of biotherapies in the treatment of chronic diseases and allows their proper implementation), growth reached 10.1%
The historical in vitro diagnostics business posted sales up 9.2% to 5.8 million euros.
As of December 31, 2022, Theradiag’s cash amounted to 6.4 million euros compared to 7.1 million euros as of December 31, 2021, a level deemed ‘in line with the company’s operating plan’.
Following its takeover bid, which closed last week, Biosynex held more than 68.8% of the capital and at least 68.6% of the voting rights of Theradiag, which means that the condition minimum requirement the offer is satisfied.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.